Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey ...

Kayla Jones: "I never thought I'd need an organ. Never in my wildest dreams did I think I would need an organ at 35." ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

Bristol Myers Squibb’s (BMS) dual immunotherapy combination has been recommended by the European Medicines Agency’s human ...

The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the forefront of cancer care. PLYMOUTH MEETING, Pa., Feb. 4, 2025 ...